Complex | |
AACDB_ID: | 6830 |
PDBID: | 4GRW |
Chains: | J_A |
Organism: | Homo sapiens, Lama glama |
Method: | XRD |
Resolution (Å): | 2.55 |
Reference: | 10.3389/fimmu.2017.00884 |
Antibody | |
Antibody: | 37D5 Nanobody |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | Interleukin-23 subunit alpha (IL-23 α) |
Antigen mutation: | No |
Durg Target: | Q9NPF7 |
Antibody
Chain: J
Mutation: NULL
>4GRW_J|Chain F, J|Nanobody 37D5|Lama glama (9844) EVQLVESGGGLVQPGGSLRLSCAASGFTLDYLAIGWFRQAPGKEREGVSCVSSSGQYTYYADSVKGRFTISRDNAESTVYLQMNSLKPEDTAVYYCATDPECYRVRGYYNGEYDYWGQGTQVTVSS |
Antigen
Chain: A
Mutation: NULL
>4GRW_A|Chain A, C|Interleukin-23 subunit alpha|Homo sapiens (9606) MLGSRAVMLLLLLPWTAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEGDEETTNDVPHIQCGDGCDPQGLRDNSQFCLQRIHQGLIFYEKLLGSDIFTGEPSLLPDSPVGQLHASLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAARVFAHGAATLSP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
J: PHE27 THR28 ASP30 TYR31 LEU32 ALA33 SER52 SER53 SER54 TYR57 TYR59 THR98 PRO100 GLU101 CYS102 TYR103 ARG106 TYR108 TYR109 ASN110 GLY111 A: LEU24 TRP26 SER27 ALA28 HIS29 PRO30 GLU93 PRO94 SER95 LEU96 LEU97 PRO98 ASP99 SER100 PRO101 VAL102 GLN104 TRP137 GLN138 LEU140 LEU141 ARG143 PHE144 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)